Weifa ASA (WEIFA) - Financial and Strategic SWOT Analysis Review

May 2017 | 41 pages | ID: W065B5FB7AEEN
GlobalData

Abstracts

Weifa ASA (WEIFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering products for pain relief; treatment of cough and colds; dermatology; Nutraceuticals; dietary supplements; and wound treatment among others. Its research and development activities focus on prescription drug products, OTC products and nutraceuticals. It offers products to consumers, customers and professional partners. The company has operational presence in Denmark, Iceland, Sweden and Finland. Weifa is headquartered in Oslo, Norway.

Weifa ASA Key Recent Developments

Apr 27,2017: Weifa: Record First-Quarter Revenues Driven by Organic Growth
Oct 25,2016: Weifa: Record Third-Quarter Revenues and Growth for all Main Categories
Oct 11,2016: Weifa ASA to launch Ibux 200 mg soft capsules to strengthen its pain relief portfolio
Sep 14,2016: Weifa to launch Solvivo - a new OTC product for sore throat in Norway
Aug 25,2016: Weifa: Second Quarter 2016 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

strong>SECTION 1 - ABOUT THE COMPANY

Weifa ASA - Key Facts
Weifa ASA - Key Employees
Weifa ASA - Key Employee Biographies
Weifa ASA - Major Products and Services
Weifa ASA - History
Weifa ASA - Company Statement
Weifa ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Weifa ASA - Business Description
Weifa ASA - Corporate Strategy
Weifa ASA - SWOT Analysis
SWOT Analysis - Overview
Weifa ASA - Strengths
Weifa ASA - Weaknesses
Weifa ASA - Opportunities
Weifa ASA - Threats
Weifa ASA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, OIL & GAS FINANCIAL DEALS AND ALLIANCES

Weifa ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Weifa ASA, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 27, 2017: Weifa: Record First-Quarter Revenues Driven by Organic Growth
Oct 25, 2016: Weifa: Record Third-Quarter Revenues and Growth for all Main Categories
Oct 11, 2016: Weifa ASA to launch Ibux 200 mg soft capsules to strengthen its pain relief portfolio
Sep 14, 2016: Weifa to launch Solvivo - a new OTC product for sore throat in Norway
Aug 25, 2016: Weifa: Second Quarter 2016 Results
Jun 06, 2016: Weifa: Distribution agreement in Finland for unique pain products
Apr 26, 2016: Weifa: Record first-quarter revenues and proposed dividend

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Weifa ASA, Key Facts
Weifa ASA, Key Employees
Weifa ASA, Key Employee Biographies
Weifa ASA, Major Products and Services
Weifa ASA, History
Weifa ASA, Subsidiaries
Weifa ASA, Key Competitors
Weifa ASA, Ratios based on current share price
Weifa ASA, Annual Ratios
Weifa ASA, Annual Ratios (Cont.1)
Weifa ASA, Annual Ratios (Cont.2)
Weifa ASA, Interim Ratios
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Weifa ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Weifa ASA, Performance Chart (2012 - 2016)
Weifa ASA, Ratio Charts
Weifa ASA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Weifa ASA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Serodus ASA
Saipem Norge AS
Novartis Oncology
Lytix Biopharma AS
Halliburton AS